| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5859006 | LILLY | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(6 years ago) | |
| US6821975 | LILLY | Beta-carboline drug products |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6140329 | LILLY | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Jul, 2016
(7 years ago) | |
|
US5859006 (Pediatric) | LILLY | Tetracyclic derivatives; process of preparation and use |
May, 2018
(5 years ago) | |
| US7182958 | LILLY | β-carboline pharmaceutical compositions |
Apr, 2020
(4 years ago) | |
| US6943166 | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Apr, 2020
(4 years ago) | |
|
US6943166 (Pediatric) | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Oct, 2020
(3 years ago) | |
|
US7182958 (Pediatric) | LILLY | β-carboline pharmaceutical compositions |
Oct, 2020
(3 years ago) | |
|
US6821975 (Pediatric) | LILLY | Beta-carboline drug products |
May, 2021
(2 years ago) | |
Cialis is owned by Lilly.
Cialis contains Tadalafil.
Cialis has a total of 9 drug patents out of which 9 drug patents have expired.
Expired drug patents of Cialis are:
- US6140329
- US5859006*PED
- US7182958
- US6943166
- US6943166*PED
- US7182958*PED
- US6821975*PED
- US5859006
- US6821975
Cialis was authorised for market use on 07 January, 2008.
Cialis is available in tablet;oral dosage forms.
Cialis can be used as treatment of erectile dysfunction, erectile dysfunction.
The generics of Cialis are possible to be released after 15 August, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-219) | Feb 15, 2021 |
| Pediatric Exclusivity(PED) | Aug 15, 2021 |
| New Indication(I-642) | Oct 06, 2014 |
| New Indication(I-641) | Oct 06, 2014 |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 07 January, 2008
Treatment: Treatment of erectile dysfunction; Erectile dysfunction
Dosage: TABLET;ORAL
CIALIS family patents
